Matches in Wikidata for { <http://www.wikidata.org/entity/Q87869327> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q87869327 description "article scientifique publié en 2014" @default.
- Q87869327 description "artículu científicu espublizáu en mayu de 2014" @default.
- Q87869327 description "scientific article published on 14 May 2014" @default.
- Q87869327 description "wetenschappelijk artikel" @default.
- Q87869327 description "наукова стаття, опублікована в травні 2014" @default.
- Q87869327 name "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 name "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 type Item @default.
- Q87869327 label "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 label "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 prefLabel "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 prefLabel "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 P1433 Q87869327-A77A41EA-DD0C-4C77-9DA2-AB1CFCAB9C43 @default.
- Q87869327 P1476 Q87869327-67347059-656C-4EE0-ACC4-1C795360E456 @default.
- Q87869327 P2093 Q87869327-057D4BC1-E56B-4E14-91B3-2DD035AD38F4 @default.
- Q87869327 P2093 Q87869327-1CD6C8FC-B118-4F12-9B41-9FD79C8D8ADC @default.
- Q87869327 P2093 Q87869327-367C925B-2954-4287-AD12-8F025FD6C0E3 @default.
- Q87869327 P2093 Q87869327-399736D2-A352-4B1F-BB16-7E846C8A5D63 @default.
- Q87869327 P2093 Q87869327-50120FAE-48A9-4CCA-8951-C7549A3BF850 @default.
- Q87869327 P2093 Q87869327-7382DA0F-F0C1-4C96-8017-249D1A3F9BFC @default.
- Q87869327 P2093 Q87869327-7CD77FCB-FAE4-4886-982B-169EA712A4C4 @default.
- Q87869327 P2093 Q87869327-7EA83F79-B12A-4A98-B364-48683EF4AAF3 @default.
- Q87869327 P2093 Q87869327-7F13FD41-799C-4EB2-BEDD-B47971BBAFC7 @default.
- Q87869327 P2093 Q87869327-802C9932-8141-4CDB-9E7C-F5163018FE0D @default.
- Q87869327 P2093 Q87869327-9B292084-C64D-421D-BFE6-014B2A9E815B @default.
- Q87869327 P2093 Q87869327-AD96A751-8327-460C-B629-B9C52C358AEA @default.
- Q87869327 P2093 Q87869327-C20102D4-1F4F-4712-B827-90C818350F5D @default.
- Q87869327 P2093 Q87869327-C76A8347-B18F-42CC-A45E-BDF56B384F9E @default.
- Q87869327 P2093 Q87869327-D5503508-DC4A-4091-8A8E-77AF65BF7F86 @default.
- Q87869327 P2093 Q87869327-F3AEB8B6-5C54-46A0-81FD-D64EB7F739AE @default.
- Q87869327 P304 Q87869327-E455BD7F-CD2A-44E6-B757-CA3493BAE28D @default.
- Q87869327 P31 Q87869327-1C027348-120B-46B2-9CEC-92A36ECC91B5 @default.
- Q87869327 P356 Q87869327-417698D1-57D6-4F13-BCC0-F843E5209525 @default.
- Q87869327 P433 Q87869327-9279ED23-7DF8-4D93-AFF5-88301FB6D818 @default.
- Q87869327 P478 Q87869327-D8FB496B-AE54-400A-A4F4-F1DEEF1777DC @default.
- Q87869327 P50 Q87869327-5CD748F3-CD29-4DE2-B1E9-DE9F0400DBAD @default.
- Q87869327 P50 Q87869327-BBFD47DC-EA62-4F7D-8463-2B4C2D0BD513 @default.
- Q87869327 P577 Q87869327-D5E32FBE-DE60-4832-9D0F-43F096E12187 @default.
- Q87869327 P698 Q87869327-ED03ECB9-4A09-4BB7-AEAA-ADB8BF623F37 @default.
- Q87869327 P921 Q87869327-5FBF41A6-D6D3-47DF-9454-7E1D41DAD27E @default.
- Q87869327 P921 Q87869327-EBD7F57D-B53C-4FB6-8B92-D9AEAA6E3A91 @default.
- Q87869327 P356 S00280-014-2482-0 @default.
- Q87869327 P698 24824852 @default.
- Q87869327 P1433 Q326137 @default.
- Q87869327 P1476 "Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer" @default.
- Q87869327 P2093 "Catherine Lassabe" @default.
- Q87869327 P2093 "Christophe Borg" @default.
- Q87869327 P2093 "Denis Cleau" @default.
- Q87869327 P2093 "Francine Fein" @default.
- Q87869327 P2093 "Franck Bonnetain" @default.
- Q87869327 P2093 "Laurent Arnould" @default.
- Q87869327 P2093 "Marine Jary" @default.
- Q87869327 P2093 "Marion Jacquin" @default.
- Q87869327 P2093 "Maryame El Gani" @default.
- Q87869327 P2093 "Najib Lamfichekh" @default.
- Q87869327 P2093 "Pierre Mathieu" @default.
- Q87869327 P2093 "Serge Fratté" @default.
- Q87869327 P2093 "Sophie Paget-Bailly" @default.
- Q87869327 P2093 "Séverine Valmary-Degano" @default.
- Q87869327 P2093 "Thierry Nguyen" @default.
- Q87869327 P2093 "Virginie Nerich" @default.
- Q87869327 P304 "141-150" @default.
- Q87869327 P31 Q13442814 @default.
- Q87869327 P356 "10.1007/S00280-014-2482-0" @default.
- Q87869327 P433 "1" @default.
- Q87869327 P478 "74" @default.
- Q87869327 P50 Q42540278 @default.
- Q87869327 P50 Q59388255 @default.
- Q87869327 P577 "2014-05-14T00:00:00Z" @default.
- Q87869327 P698 "24824852" @default.
- Q87869327 P921 Q423762 @default.
- Q87869327 P921 Q61913382 @default.